Additionally, the study by Park et al. [56] found that non-responsive CRC-PDOs to butyrate and radiation combination therapy had lower levels of FOXO3A expression compared to responsive CRC-PDOs. The gene discussed is FOXO3; the disease is colorectal carcinoma.